Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 373Thoracic 44Gynecologic 34Breast 30Genitourinary 26Head & Neck 25Sarcoma 13Endocrine 9Dermatologic 8NET 6Other solid neoplasm 5CNS 4Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3082Neoplasms, Plasma Cell 614Lymphoma 455Lymphoma, Non-Hodgkin 428Recurrence 371Hodgkin Disease 366Leukemia, Lymphocytic, Chronic, B-Cell 362Precursor Cell Lymphoblastic Leukemia-Lymphoma 340Leukemia, Myeloid, Acute 322Leukemia 321Myelodysplastic Syndromes 287Lymphoma, Mantle-Cell 262Lymphoma, Large B-Cell, Diffuse 259Lymphoma, Follicular 254Lymphoma, B-Cell, Marginal Zone 231Burkitt Lymphoma 227Lymphoma, Large-Cell, Immunoblastic 203Myeloproliferative Disorders 197Immunoglobulin Light-chain Amyloidosis 184Neoplasms 182Hematologic Neoplasms 169Primary Myelofibrosis 167Leukemia, Myeloid, Chronic-Phase 165Leukemia, Myeloid, Accelerated Phase 154Lymphoma, T-Cell, Cutaneous 150Waldenstrom Macroglobulinemia 145Blast Crisis 143Leukemia, Myelomonocytic, Chronic 140Mycosis Fungoides 129Sezary Syndrome 128

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × Plasma cell × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡